NCT07237412 Neurofeedback-based Visual Restoration Therapy
| NCT ID | NCT07237412 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Adrian Guggisberg |
| Condition | Visual Field Defect Homonymous Bilateral |
| Study Type | INTERVENTIONAL |
| Enrollment | 14 participants |
| Start Date | 2025-11-17 |
| Primary Completion | 2028-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 14 participants in total. It began in 2025-11-17 with a primary completion date of 2028-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Visual field defects are a common consequence of acquired brain injuries and affect people of all ages. These vision problems make everyday life more difficult-for example, when reading, driving, or moving around safely. However, there is currently no effective therapy to improve visual field defects. Previous training methods have focused on maximizing brain activity during a task. However, new findings show that the best performance is achieved when the brain is already in a state of high communication before the task. Our research shows that people can learn to increase communication between brain regions through neurofeedback. Studies have shown that neurofeedback can help people after a stroke: it improves the coordination of brain areas that are important for movement, thereby helping to increase mobility. Building on these findings, this study investigates whether EEG neurofeedback can support the visual centers in the brain to improve vision in patients with chronic visual field defects. The main objective of the study is to evaluate the effectiveness of neurofeedback in improving visual field defects. More specifically, the investigators are investigating the development of visual ability (expansion of the visual field, contrast sensitivity).
Eligibility Criteria
Inclusion Criteria: * Chronic, stable HVFD (homologous lateral quadranopsia or hemianopsia) * 12 months or more after stroke * Age range 50-70 * Ability to provide informed consent Exclusion Criteria: * Inability to concentrate for long treatment sessions * Eye disease with impact on visual field or acuity * Presence of non-MRI safe metal in the body * New stroke during study period * Hemispatial neglect
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07237412 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 70 Years, studying Visual Field Defect Homonymous Bilateral. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07237412 currently recruiting?
Yes, NCT07237412 is actively recruiting participants. Contact the research team at adrian.guggisberg@hug.ch for enrollment information.
Where is the NCT07237412 trial being conducted?
This trial is being conducted at Bern, Switzerland, Geneva, Switzerland.
Who is sponsoring the NCT07237412 clinical trial?
NCT07237412 is sponsored by Adrian Guggisberg. The trial plans to enroll 14 participants.